Utilization and Expenditure of Anti-cancer Medicines in Kosovo: Findings and Implications

PharmacoEconomics - Open

Volumn 2, Issue 4, 2018, Pages 423-432

  Jakupi, Arianit ^a,b   Godman, Brian ^c,d,e   Martin, Antony ^e   Haycox, Alan ^e   Baholli, Indrit ^f  

^a UNIVERSITY FOR BUSINESS AND TECHNOLOGY   (Serbia)

^b Pharmaceutical Consulting   (Serbia)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^f EUROPEAN UNIVERSITY OF TIRANA   (Albania)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; BEVACIZUMAB; BLEOMYCIN; CAPECITABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; ERLOTINIB; FILGRASTIM; GOSERELIN; IFOSFAMIDE; IMATINIB; INTERFERON; INTERFERON BETA SERINE; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PEGINTERFERON ALPHA2A; PEMETREXED; PROCARBAZINE; RITUXIMAB; SORAFENIB; TAMOXIFEN; TEMOZOLOMIDE; TIOGUANINE; TOCILIZUMAB; TRASTUZUMAB; UNINDEXED DRUG; VINCRISTINE;

AMBULATORY CARE; ARTICLE; DRUG COST; DRUG UTILIZATION; HUMAN; KOSOVO; ONCOLOGY; PRIORITY JOURNAL;

EID: 85051696492     PISSN: 25094262     EISSN: 25094254     Source Type: Journal    
DOI: 10.1007/s41669-017-0066-8     Document Type: Article

References (46)

1. Godman B, Wettermark B, van Woerkom M, Fraeyman J, Alvarez-Madrazo S, Berg C, et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front Pharmacol. 2014;5:106
2. Wettermark B, Godman B, Neovius M, Hedberg N, Mellgren TO, Kahan T. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy. 2010;94(3):221–9
3. Wettermark B, Zoega H, Furu K, Korhonen M, Hallas J, Norgaard M, et al. The Nordic prescription databases as a resource for pharmacoepidemiological research—a literature review. Pharmacoepidemiol Drug Saf. 2013;22(7):691–9
4. Sakshaug S, Furu K, Karlstad O, Ronning M, Skurtveit S. Switching statins in Norway after new reimbursement policy: a nationwide prescription study. Br J Clin Pharmacol. 2007;64(4):476–81
5. Haycox A. Why cancer? Pharmacoeconomics. 2016;34(7):625–7
6. New 50 million pound cancer fund already intellectually bankrupt. Lancet. 2010;376(9739):389
7. Kelly RJ, Smith TJ. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. Lancet Oncol. 2014;15(3):e112–8
8. WHO. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. http://www.euro.who.int/__data/assets/pdf_file/0008/306179/Access-new-medicines-TR-PIO-collaboration-research.pdf?ua=1. Accessed 16 May 2017
9. Barrett A, Roques T, Small M, Smith RD. How much will Herceptin really cost? BMJ. 2006;333(7578):1118–20
10. Ghinea H, Kerridge I, Lipworth W. If we don’t talk about value, cancer drugs will become terminal for health systems. http://theconversation.com/if-we-dont-talk-about-value-cancer-drugs-will-become-terminal-for-health-systems-44072. Accessed 10 May 2017
11. Matusewicz W, Godman B, Pedersen HB, Furst J, Gulbinovic J, Mack A, et al. Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe. Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):755–8
12. Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: the European experience. Brussels: EMiNet; 2013. http://eprints.lse.ac.uk/50513/. Accessed 29 Apr 2017
13. Ministry of Health of Kosovo. Health sectorial strategy 2017–2021. 2017. http://www.kryeministri-ks.net/repository/docs/Strategjia-sektoriale-e-shendetesise-final-nentor-2016-ALB.pdf. Accessed 28 Apr 2017
14. Statistical Agency of Kosovo. Health statistics in 2015. 2016. http://ask.rks-gov.net/sq/agjencia-e-statistikave-te-kosoves/sociale/shendetesia-dhe-mireqenia-sociale. Accessed 26 Apr 2017
15. Lopert R. Republic of Kosovo—review of oncology formulary. World Bank Report. 2014. Washington, DC: World Bank; 2015
16. Quick JD, Hogerzeil H Hogerzeil, Rankin, JR, Dukes MNG, Laing R, et al. (eds). Economics, pharmaceuticals in managing drug supply: the selection, procurement, distribution, and use of pharmaceuticals. Management sciences for health in collaboration with the World Health Organization. West Hartford: Kumarian Press; 1997. http://apps.who.int/iris/handle/10665/41908. Accessed 4 May 2017
17. Transparentitis virus: public procurement monitoring at the Ministry of Health. 2016. http://www.kdi-kosova.org/publikime/74-2016-03-31-virusi-transparentitis_eng_final_isbn.pdf. Accessed 4 May 2017
18. WHO. Antimicrobial Medicines Consumption (AMC) Network. AMC data 2011–2014. 2017. http://www.euro.who.int/en/publications/abstracts/antimicrobial-medicines-consumption-amc-network.-amc-data-20112014-2017. Accessed 6 May 2017
19. Alvarez-Madrazo S, McTaggart S, Nangle C, Nicholson E, Bennie M. Data resource profile: the Scottish National Prescribing Information System (PIS). Int J Epidemiol. 2016;45(3):714
20. Wallerstedt SM, Wettermark B, Hoffmann M. The first decade with the Swedish Prescribed Drug Register—a systematic review of the output in the scientific literature. Basic Clin Pharmacol Toxicol. 2016;119(5):464–9
21. Wettermark B, Zoega H, Furu K, Korhonen M, Hallas J, Nørgaard M. The Nordic prescription databases as a resource for pharmacoepidemiological research—a literature review. Pharmacoepidemiol Drug Saf. 2013;22:691
22. Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, et al. Policies to enhance prescribing efficiency in europe: findings and future implications. Front Pharmacol. 2010;1:141
23. Markovic-Pekovic V, Skrbic R, Godman B, Gustafsson LL. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions. Expert Rev Pharmacoecon Outcomes Res. 2012;12(5):661–71
24. Kalaba M, Godman B, Vuksanovic A, Bennie M, Malmstrom RE. Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history? J Comp Eff Res. 2012;1(6):539–49
25. Voncina L, Strizrep T, Godman B, Bennie M, Bishop I, Campbell S, et al. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev Pharmacoecon Outcomes Res. 2011;11(4):469–79
26. Kosovo Medicines Agency. Pharmacies in Kosovo 2017. https://cloud.akppm.com/public.php?service=files&t=e13af25d11ae958885f3c201a595b6af. Accessed 20 Apr 2017
27. Krasniqi SH. Drug register 4. Prishtinë Kosovë: Kosovo Medicines Agency; 2015
28. Ministry of Health of Kosovo. Analysis of the essential list for 2013 including VEN and ABC indicators. Kosovo: Prishtina; 2015
29. Jakupi A. Drug consumption in Kosovo 2011–2013. Prishtinë Kosovë: Kosovo Medicines Agency. http://akppm.com/. Accessed 20 Apr 2017
30. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index. https://www.whocc.no/atc_ddd_index/?. Accessed 10 Apr 2017
31. Bachhav SS, Kshirsagar NA. Systematic review of drug utilization studies and the use of the drug classification system in the WHO-SEARO Region. Indian J Med Res. 2015;142(2):120–9
32. Chlabicz M, Chlabicz S, Marcinowicz L, Rogowska-Szadkowska D, Pytel-Krolczuk B, Leszczynska K. Outpatient use of systemic antibiotics in Poland: 2004–2008. Przegl Epidemiol. 2014;68(3):435–41
33. Versporten A, Bolokhovets G, Ghazaryan L, Abilova V, Pyshnik G, Spasojevic T, et al. Antibiotic use in eastern Europe: a cross-national database study in coordination with the WHO Regional Office for Europe. Lancet Infect Dis. 2014;14(5):381–7
34. Dumartin C, L’Heriteau F, Pefau M, Bertrand X, Jarno P, Boussat S, et al. Antibiotic use in 530 French hospitals: results from a surveillance network at hospital and ward levels in 2007. J Antimicrob Chemother. 2010;65(9):2028–36
35. WHO. Analyzing and controlling pharmaceutical expenditures. http://apps.who.int/medicinedocs/documents/s19617en/s19617en.pdf. Accessed 4 May 2017
36. Holloway K, Green T on behalf of the WHO in collaboration with Management Sciences for Health. Drug and therapeutics committees: a practical guide. http://apps.who.int/medicinedocs/pdf/s4882e/s4882e.pdf. Accessed 4 May 2017
37. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. 2017. https://www.whocc.no/filearchive/publications/guidelines.pdf. Accessed 4 Jan 2018
38. WHO. Introduction to drug utilization research. http://apps.who.int/medicinedocs/pdf/s4876e/s4876e.pdf. Accessed 10 Apr 2017
39. Sakshaug S, Strøm H, Berg C, Blix HS, Litleskare I, Granum T. Legemiddelforbruket i Norge 2012–2016 [Drug consumption in Norway 2012–2016]. Oslo: Folkehelseinstituttet/Norwegian Institute of Public Health; 2016
40. Webber-Foster R, Kvizhinadze G, Rivalland G, Blakely T. Cost-effectiveness analysis of docetaxel versus weekly paclitaxel in adjuvant treatment of regional breast cancer in New Zealand. Pharmacoeconomics. 2014;32(7):707–24
41. NHS CeVEAS. Review of the available evidence on taxanes (paclitaxel and docetaxel) for breast cancer for the inclusion in the WHO Model List of Essential Medicines. http://www.who.int/selection_medicines/committees/expert/18/applications/8_submission_taxanes.pdf. Accessed 10 May 2017
42. WHO. WHO Model List of Essential Medicines—March 2017; Amended August 2017. http://www.who.int/medicines/publications/essentialmedicines/20th_EML2017_FINAL_amendedAug2017.pdf?ua=1. Accessed 1 Sept 2017
43. Godman B, Oortwijn W, de Waure C, Mosca I, Puggina A, Specchia ML et al. Links between Pharmaceutical R&D models and access to affordable medicines. A study for the ENVI Committee. http://www.europarl.europa.eu/RegData/etudes/STUD/2016/587321/IPOL_STU(2016)587321_EN.pdf. Accessed 10 May 2017
44. Kibuule D, Mubita M, Naikaku E, Kalemeera F, Godman BB, Sagwa E. An analysis of policies for cotrimoxazole, amoxicillin and azithromycin use in Namibia’s public sector: findings and therapeutic implications. Int J Clin Pract. 2017;71(2). 10.1111/ijcp.12918
45. Pallis A, Tsiantou V, Simou E, Maniadakis N. Pharmacoeconomic considerations in the treatment of breast cancer. ClinicoEcon Outcomes Res. 2010;2:47–61
46. Bjorkhem-Bergman L, Andersen-Karlsson E, Laing R, Diogene E, Melien O, Jirlow M, et al. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. Eur J clin pharmacol. 2013;69:73–8